Article

Rate-dependent effects of bupropion on nicotine self-administration and food-maintained responding in rats.

Department of Psychology, Jacksonville State University, 700 Pelhan Road North, Jacksonville, AL 36265, USA.
Pharmacology Biochemistry and Behavior (Impact Factor: 2.82). 07/2008; 90(4):701-11. DOI: 10.1016/j.pbb.2008.05.014
Source: PubMed

ABSTRACT Bupropion has been found to be a useful pharmaceutical agent in furthering smoking abstinence. Preclinical research investigating the effects of bupropion on nicotine self-administration has indicated bupropion has selective effects on nicotine self-administration. However since response rates maintained by nicotine were significantly lower than rates of response maintained by the non-drug reinforcers, bupropion may have resulted in rate-dependent effects. The current experiments attempted to decrease the high response rate maintained through non-drug reinforcers in order to have more comparable control rates when investigating the selectivity of bupropion for nicotine self-administration. The effects of bupropion on nicotine self-administration (0.03 mg/kg/inf) were compared to food-maintained responding at two levels of food deprivation (deprived and satiated). Rats were satiated prior to the experimental session in order to decrease the overall response rates maintained through food reinforcement. Bupropion increased nicotine intake, but dose-dependently decreased food intake, when rats were food-deprived. However, when more comparable rates of behavior in the food-satiated group were investigated, bupropion had similar effects on nicotine and food-maintained responding. The data indicate that the effects of bupropion can be influenced by the control rate of responding. The results from these experiments also indicate that bupropion may not exert a selective effect on nicotine self-administration, since low rates of food and drug maintained responding were increased by the drug. These results indicate the importance of controlling for differences in response rates when attempting to assess the effects of drugs on responding maintained by different reinforcers. Furthermore, the results from the present study suggest that motivational variables (i.e. food deprivation) may be used to control for response rate differences maintained by drug and non-drug reinforcers.

0 Followers
 · 
80 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nicotine serves as a primary reinforcer but also potently enhances responding for nonnicotine stimuli with reinforcing properties. One of the most successful pharmacotherapies for smoking cessation, bupropion, also increases responding for nondrug reinforcers such as food and brain stimulation rewards. The present studies investigated whether treatment with bupropion and nicotine had similar effects on responding for a reinforcing visual stimulus (VS). They also investigated whether the effects of bupropion and nicotine depended on common pharmacological substrates. Nicotine (0.4 mg/kg base) enhanced responding for the VS, and this enhancing effect increased across testing sessions, replicating our previous findings. Bupropion (3, 10, and 30 mg/kg salt) dose-dependently increased responding for the VS. Treatment with 10 and 30 mg/kg bupropion resulted in a profile similar to nicotine; operant responding increased over repeated drug treatments. The reinforcement enhancing effect of nicotine, but not bupropion, was blocked by pretreatment with the nicotinic acetylcholine receptor antagonist mecamylamine. In contrast, the reinforcement enhancing effect of bupropion, but not nicotine, was blocked by pretreatment with the alpha noradrenergic antagonist prazosin. The reinforcement enhancing effects of nicotine and bupropion increased over time and repeated treatments suggesting a shared mechanism of action. However, the reinforcement enhancing effects of nicotine are mediated by nicotinic acetylcholine receptors, whereas the reinforcement enhancing effects of bupropion were mediated by alpha noradrenergic receptors.
    Psychopharmacology 09/2009; 207(3):381-90. DOI:10.1007/s00213-009-1666-5 · 3.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bupropion is a promising candidate medication for methamphetamine use disorder. As such, we used a preclinical model of drug-taking to determine the effects of bupropion on the reinforcing effects of methamphetamine (0.025, 0.05 or 0.1 mg/kg/infusion). Specificity was determined by investigating the effects of bupropion on responding maintained by sucrose. In the self-administration study, rats were surgically prepared with indwelling jugular catheters and trained to self-administer methamphetamine under an FR5 schedule. A separate group of rats was trained to press a lever for sucrose. Once responding stabilized, rats were pretreated with bupropion (0, 10, 30 and 60 mg/kg i.p.) 5 min before chamber placement in a unique testing order. Following acute testing, rats were then repeatedly pretreated with 30 and 60 mg/kg bupropion. Acute treatments of bupropion dose dependently reduced drug intake for 0.025-0.1 mg/kg methamphetamine; sucrose deliveries were only reduced with the high bupropion dose. Repeated exposure to 60 mg/kg bupropion before the session resulted in a consistent decrease in methamphetamine intake (0.05 and 0.1 mg/kg) and sucrose deliveries. Considered together, this pattern of findings demonstrates that bupropion decreases responding for methamphetamine, but the effects are only somewhat specific.
    Drug and alcohol dependence 12/2008; 100(1-2):54-62. DOI:10.1016/j.drugalcdep.2008.09.006 · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline has greater efficacy than other pharmacotherapeutic aids for smoking cessation. This presents an opportunity to evaluate the predictive validity of rat models of nicotine taking and relapse. The aim of this study was to evaluate the ability of varenicline to attenuate nicotine self-administration and relapse, as modelled by the reinstatement model of nicotine relapse in rats. Rats were trained to respond for intravenous nicotine under a fixed ratio schedule of reinforcement. The effects of varenicline (0.3-3.0 mg/kg s.c.) on both nicotine and food self-administration and reinstatement of nicotine seeking were evaluated. Varenicline dose-dependently reduced nicotine self-administration and attenuated both nicotine prime and combined nicotine prime plus nicotine-paired cue-induced reinstatement. Varenicline had no effect on cue-induced reinstatement in the absence of a nicotine prime nor did it induce reinstatement when given alone. The effects of varenicline on nicotine-induced reinstatement of drug-seeking are consistent with the demonstrated clinical efficacy of varenicline for smoking cessation.
    Psychopharmacology 12/2009; 208(3):365-76. DOI:10.1007/s00213-009-1739-5 · 3.99 Impact Factor

Preview

Download
0 Downloads
Available from